Trastuzumab-resistant breast cancer: buparlisib fails phase 2 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Buparlisib (BKM120) plus trastuzumab demonstrated a favorable safety profile but limited efficacy in a phase 2 trial of patients with trastuzumab-resistant, locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer.
  • No maximum tolerate...